Yap Bioceuticals

Yap Bioceuticals is a biotechnology company focused on developing novel small molecule therapeutics that target the Hippo signaling pathway, specifically the YAP/TAZ transcriptional co-activators. The company's research centers on inhibiting the overactivation of YAP and TAZ, which are known drivers of tumor growth, drug resistance, and metastasis in various solid tumors. By leveraging deep expertise in the Hippo pathway, Yap Bioceuticals aims to create precision medicines for cancers with high unmet needs, such as mesothelioma and certain types of lung and liver cancers. The company is currently in the pre-clinical stage, advancing a pipeline of potent and selective inhibitors designed to disrupt the interaction between YAP/TAZ and TEAD transcription factors.